Zoetis Inc. $ZTS Shares Acquired by BlueSpruce Investments LP

BlueSpruce Investments LP increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 21,663.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 752,351 shares of the company’s stock after acquiring an additional 748,894 shares during the period. Zoetis makes up about 2.7% of BlueSpruce Investments LP’s investment portfolio, making the stock its 12th largest position. BlueSpruce Investments LP owned approximately 0.17% of Zoetis worth $117,329,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the last quarter. Impax Asset Management Group plc increased its holdings in shares of Zoetis by 362.6% in the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after buying an additional 922,589 shares in the last quarter. Amundi lifted its position in shares of Zoetis by 30.8% during the 1st quarter. Amundi now owns 3,595,628 shares of the company’s stock valued at $575,691,000 after acquiring an additional 846,909 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Zoetis by 126.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,470,742 shares of the company’s stock worth $229,362,000 after acquiring an additional 822,334 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS stock opened at $118.60 on Friday. The firm has a 50 day simple moving average of $130.95 and a 200 day simple moving average of $146.22. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $181.85. The stock has a market cap of $52.26 billion, a P/E ratio of 19.97, a P/E/G ratio of 2.44 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio is presently 33.67%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ZTS shares. Morgan Stanley cut their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday, November 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Stifel Nicolaus dropped their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Finally, Barclays assumed coverage on shares of Zoetis in a report on Monday. They set an “equal weight” rating and a $136.00 price target on the stock. Five analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $164.20.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.